More Eyedrops Recalled Due to Infection Danger
By Cara Murez HealthDay Reporter
THURSDAY, Nov. 2, 2023 -- Cardinal Health, Inc. is voluntarily recalling certain LEADER brand eyedrops because they may cause eye infections.
The U.S. Food and Drug Administration informed the Dublin, Ohio, company that agency investigators found unsanitary conditions in its manufacturing facility. Tests of critical drug production areas of the facility were positive for bacteria.
The drops were supplied by Velocity Pharma, LLC.
Potential eye infections caused by bacteria could lead to partial vision loss or blindness, Cardinal Health warned in a recall notice from the FDA.
These products were meant to be sterile. Contaminated ophthalmic drug products pose a particular risk of harm because products applied to the eyes bypass some of the body’s natural defenses.
Cardinal Health has received reports of three adverse events related to these listed products and have shared this information with its supplier, the recall notice said.
Several products are part of the recall.
They are:
-
LEADER Eye Irritation Relief, NDC code 70000-0087-1
-
LEADER Dry Eye Relief, NDC code 70000-0089-1
-
LEADER Lubricant Eye Drops, NDC code 70000-0090-1
-
LEADER Lubricant Eye Drops, NDC codes 70000-0090-2 (pack of 2) and 70000-0090-1 (bottle)
-
LEADER Dry Eye Relief, NDC code 70000-0088-1
-
LEADER Lubricant Eye Drops, NDC code 70000-0587-1
These eyedrops are sold over the counter for temporary relief of burning and irritation due to dryness, to protect against further irritation and to relieve redness.
They were sent to wholesalers and retailers starting in December 2021.
While the company is notifying its direct accounts via mail and arranging for return of the products, wholesalers, distributors and retailers should stop selling the eyedrops.
Consumers should also stop using them. They may return any of the recalled products to place they bought them.
Talk to your doctor or seek medical care immediately if you have signs or symptoms of an eye infection.
Contact Sedgwick, Inc. with questions by phone at 855-215-4940 from 8 a.m. to 5 p.m. EST weekdays, or by email at Cardinalhealth7720@sedgwick.com.
Report adverse events to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Sources
- U.S. Food and Drug Administration, news release, Nov. 1, 2023
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Utah Kids Got E. Coli From Playing Around Lawn Sprinklers
FRIDAY, May 10, 2024 -- Happily jumping around lawn sprinklers or playing with garden hoses on a hot summer day: An idyllic childhood scene. Not so for a bunch of kids in Utah...
Americans Got Drug-Resistant Infections After Stem Cell Treatments in Mexico
THURSDAY, May 9, 2024 -- Antibiotic-resistant meningitis or severe, long-lasting joint infections: That's what three U.S. "medical tourists" brought home after seeking out...
Gene Therapy Improves Vision in People With Inherited Blindness
MONDAY, May 6, 2024 -- An injectable gene therapy caused measurable improvements in vision among a small group of people with inherited blindness, an early-stage clinical trial...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
